echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Zai Lab Class 1 new drug ``Omacycline tosylate'' will be approved soon

    Zai Lab Class 1 new drug ``Omacycline tosylate'' will be approved soon

    • Last Update: 2021-12-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 10, the official website of NMPA revealed that Zai Lab's new class 1 drug ZL-2401 (Omadacycline tosylate) has entered the "under review" stage and is expected to be approved in the near future


    From: NMPA official website

    Omacycline tosylate is a systemic antibacterial drug used for acute bacterial skin and skin structure infections


    Omadacycline is a new type of broad-spectrum tetracycline derivative, aminomethylcycline, which has two dosage forms: oral and intravenous (IV), and is administered once a day


    The drug was developed by Paratek Pharmaceuticals.


    According to the Insight database, the ZL-2401 project was first approved for clinical use in July 2018, started clinical trials in December of the same year, and declared for listing in February 2020.


    Omadacycline project time axis (Insight)

    From the Insight database (http://db.


    In March 2020, Hisun issued an announcement announcing that Sun Company Huizheng (Shanghai) Pharmaceutical Technology Co.


    According to the announcement, as part of the consideration that Zai Lab granted Huizheng rights under the agreement, Huizheng paid a non-deductible advance payment of RMB 230 million to Zai Lab


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.